Immunovant (NASDAQ:IMVT – Get Rating) had its price target lifted by HC Wainwright from $21.00 to $26.00 in a report published on Monday morning, The Fly reports. HC Wainwright also issued estimates for Immunovant’s FY2026 earnings at ($1.19) EPS and FY2027 earnings at ($0.05) EPS. Several other equities research analysts have also recently commented on […]